GlassScriptPhysician profile
Chase Hiller
NPI 1417525510
$3,035.07
in general payments reported to CMS, 2019-2025
25 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $248 · 2023: $776 · 2024: $1,336 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,606.17 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $659.35 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Indivior INC. | $343.68 | 2022-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $292.68 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.70 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $233.01 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $217.28 | 2021-2025 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $211.04 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $103.45 | 2024-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $98.91 | 2021-2024 | Loreev Xr |
| Axsome Therapeutics, INC. | $85.82 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $81.07 | 2022-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $72.23 | 2024-2025 | Cobenfy |
| Luye Pharma (USA) LTD. | $44.07 | 2025 | Erzofri Extended-Release |
| Abbvie INC. | $42.12 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $42.04 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $39.95 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $36.67 | 2023-2024 | Dyanavel Xr |
| Biogen, INC. | $34.88 | 2024-2025 | Zurzuvae |
| Corium, LLC | $33.05 | 2023-2024 | Azstarys |
| Novo Nordisk INC | $25.00 | 2022 | |
| Csl Behring | $19.54 | 2021 | |
| Merck Sharp & Dohme LLC | $17.75 | 2023 | Belsomra |
| Alexion Pharmaceuticals, INC. | $16.52 | 2021 | |
| Eisai INC. | $11.90 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.36 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Hiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.